The Michigan-based pharmaceutical contract manufacturer is investing $2 billion in seven planned plants, with an injectable production facility already completed.
Join us for a high-impact roundtable where industry leaders explore how digital transformation is revolutionizing the manufacturing of new modalities—unlocking the full potential of personalized, scalable, and rapidly delivered therapies.
